Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: A prospective randomized, double blind, sham-controlled clinical trial

Gut and Liver

Volumn 6, Issue 4, 2012, Pages 427-433

  Fukunaga, Ken ^a   Yokoyama, Yoko ^a   Kamokozuru, Koji ^a   Nagase, Kazuko ^a   Nakamura, Shiro ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Granulocyte monocyte apheresis; Inflammatory bowel diseases; Maintenance treatment; Randomized controlled trial; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; EXTRACORPOREAL CIRCULATION; FEMALE; FOLLOW UP; GRANULOCYTE; HUMAN; LEUKAPHERESIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MONOCYTE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SURVIVAL; ULCERATIVE COLITIS;

EID: 84868094530     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2012.6.4.427     Document Type: Article

References (23)

1. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005;11 Suppl 1:S3-S12.
2. Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007;37:191-200.
3. Allison MC, Dhillon AP, Lewis WG. Inflammatory bowel disease. London: Mosby, 1998:9-95
4. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1-9.
5. Fukunaga K, Nagase K, Kusaka T, et al. Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. Gut Liver 2009;3:41-47.
6. Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307-321.
7. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
8. Nagase K, Fukunaga K, Ohnishi K, Kusaka T, Matoba Y, Sawada K. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant. Ther Apher Dial 2004;8:45-51.
9. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-409.
10. Yoshino T, Nakase H, Matsuura M, et al. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. Digestion 2011;84:3-9.
11. Domènech E, Hinojosa J, Esteve-Comas M, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004;20:1347-1352.
12. Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis 2008;40:731-736.
13. Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-577.
14. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
15. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-3158.
16. Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006;12:719-726.
17. Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-2038.
18. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-2995.
19. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow-up. J Gastroenterol Hepatol 2008;23:1678-1682.
20. Maiden L, Takeuchi K, Baur R, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008;14:1413-1418.
21. Schwartz D, Ferguson Jr. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. Curr Med Res Opin 2007;23:2715-2728.
22. Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:874-888.
23. Hanai H, Iida T, Takeuchi K, et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-440.